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The blood-brain-barrier hampers the entry of chemotherapeutic drugs from systemic circulation into the central nervous system (CNS), preventing accumulation of the intradural concentrations required to eradicate tumor metastases 1) . We present a case of intradural spinal metastases that manifested during systemic chemotherapy for non-Hodgkin lymphoma (NHL). The case report was conducted in accordance with the Declaration of Helsinki, and written informed consent was obtained from the patient's family.
A 62-year-old Japanese woman was referred to our hospital for severe back pain of two months' duration. She had no additional neurological disturbances. Computed tomography showed multiple osteolytic lesions in several vertebrae (Fig. 1A) . Magnetic resonance imaging (MRI) showed deformities at several vertebrae, but did not show an obvious epidural or intradural infiltration (Fig. 1B) . Fluorodeoxyglucose-positron emission tomography (FDG-PET) showed lesions in multiple lymph nodes and several vertebrae (Fig. 2  A) .
Hemotoxylin and eosin (H & E) staining of her left groin lymph node biopsy showed large neoplastic cells with hyperchromatic nuclei in a background of small lymphocytes (Fig. 2B) . Immunostaining revealed small CD3 + /CD5 + lymphocytes and abnormally large CD20 + /CD79a + cells (Fig. 2  C, 2D ). Based on these findings, she was diagnosed with NHL (diffuse large B-cell lymphoma, stage IV). She received systemic chemotherapy with eight cycles of R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisolone) in addition to fractionated radiotherapy. At the end of the final chemotherapy cycle, eight months after initial treatment, she complained of acute, progressive paraparesis. Her muscle strength had deteriorated to 2/5, and severe numbness in both lower extremities was apparent. FDG-PET confirmed successful resolution of the lesions identified on her initial examination. However, a new intradural uptake lesion, measuring 10.5 mm in diameter, was found at L2 (Fig. 3A) . Gadolinium-enhanced MRI showed an enhanced lesion in the intradural space from T12 to L5 (Fig. 3B ). Histological analysis of the cerebrospinal fluid (CSF) showed a number of atypical lymphocytes with irregular-shaped nuclei, leading to the diagnosis of intradural metastases (Fig. 3C ). For management, she underwent intrathecal chemotherapy, which has been introduced in the treatment of CNS lymphoma 1, 2) , with nine cycles of methotrexate, cytarabine, and hydrocortisone.
Four months after the intrathecal chemotherapy, an MRI showed that the enhanced-intradural lesion had almost disappeared (Fig. 4A) . Muscle strength in both lower extremities had improved to 3/5, and a rolling walking gait was possible. However, nine months after the intrathecal chemotherapy, FDG-PET showed lesions throughout her body (Fig. 4  B) . Finally, despite treatment with several systemic chemotherapies, she died of recurrent NHL 20 months after the initial systemic chemotherapy course.
The occurrence rate of epidural metastases in patients with NHL has been reported as 7.4% 3, 4) , and the rate of CNS metastases, consisting of parenchyma and leptomeninges with NHL, is 4.2-4.8% 1, 5, 6) . The common pathway to metastatic involvement of the CNS is metastasis to the subarachnoid space, referred to as leptomeningeal spread 5) . The fiveyear survival rate of R-CHOP-treated patients with nonmetastatic NHL is 87% 7) . On the other hand, the survival rate for patients with leptomeningeal meningitis is 2-6.5 months 1) . The most likely reason is that most systemically A: Four months after the intrathecal chemotherapy, sagittal T2-weighted images (fat suppression) showed that the intradural enhanced lesion had almost disappeared. B: Nine months after the intrathecal chemotherapy, FDG-PET showed lesions throughout her body, with the exception of the intradural lesion (Fig. 4B) . MRI, magnetic resonance imaging. FDG-PET, fluorodeoxyglucose-positron emission tomography.
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administered cytotoxic drugs cannot penetrate the bloodbrain barrier to achieve clinically relevant concentrations in the CSF 1) . In our case, intrathecal chemotherapy was temporarily effective for treating the intradural metastases; however, the patient eventually died of recurrent NHL.
In this patient, while minute intradural spinal metastatic lesions may have been present at the initial visit, they may have been too small to detect using the available imaging modalities. Therefore, treating physicians should collaborate with medical oncologists and carefully monitor for intradural metastases in patients with NHL during and after treatment with systemic chemotherapy.
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